EarningsQ2 2026 Earnings Report
MX:HLNN Q2 2026 EPS Results
Actual EPS$1.00
Consensus EPS$1.14
Beat/MissMissed by -$0.14
One Year Ago EPS$2.14
MX:HLNN Q2 2026 Revenue Results
Actual Revenue$130.13B
Expected Revenue$63.46B
Beat/MissBeat by +$66.67B
YoY Revenue Growth+2.23%
Earnings Announcement Details
QuarterQ2 2026
Date07/30/2026
TimeBefore Open
Conference CallThursday, July 30, 2026
MX:HLNN Upcoming Earnings
Haleon PLC's next earnings date is estimated for March 4, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a constructive operational and financial picture: solid organic growth (3.1% in the quarter), strong margin expansion (gross margin +140 bps, operating margin +120 bps) and double‑digit EPS growth, supported by supply‑chain productivity, digital/e‑commerce momentum and targeted regional execution (China, LatAm, India). However, notable near‑term headwinds remain in respiratory/cold & flu, Europe and specific Middle East markets, plus some pricing pressure in APAC from hospital channel activity. Management maintained FY guidance (3%–5%) and expects a stronger second half, suggesting confidence in execution despite the regional and category uncertainties.Company Guidance
Organic Sales Growth and Volume Improvement
Quarter organic sales growth of 3.1% (up from 2.2% in Q1) with volume/mix at +1.4%; North America delivered 3.1% growth with a 2.0% volume contribution.
Emerging Markets and China Momentum
Emerging markets showed sequential improvement at ~6.3% growth; China delivered high single-digit growth in Q2 with Douyin e‑commerce growing >100% driven by increased investment and doubled content creation.
Oral Care Strength
Oral Care grew 6.2% in Q2 (7.3% for the half year), with Sensodyne and Parodontax performing strongly and continued innovation (clinical range launches) driving penetration gains.
Pain Relief and Product Innovation
Pain relief accelerated in Q2 driven by Voltaren strength (including new 12-hour variant in China), Panadol Dual Action rollout, and share stabilization/growth in key SKUs.
Marketing Investment and Digital/E‑commerce Gains
A&P increased ~3.2% in H1 and represented ~20.9% of spend; 60% of media allocated to digital. E‑commerce grew in strong double digits — roughly twice the market rate.
Margin, FX and EPS Performance
Gross margin improved by +140 basis points and operating margin improved +120 basis points (constant currency), aided by a +40 bps FX tailwind; reported EPS grew ~12% in H1.
Supply Chain Productivity and Operating Model Savings
Supply‑chain and productivity programs are delivering structural savings; full‑year operating model savings guidance of GBP 175–200m with ~1/3 expected this year, providing P&L flexibility.
Guidance and Confidence in Back Half
Company maintained full‑year organic growth guidance of 3%–5% and expects a stronger second half, including high single‑digit operating profit growth in H2 and continued EPS growth.
Regional Turnarounds and Execution Wins
Latin America accelerated from low‑single to high‑single digit in Q2 following targeted pricing and execution (e.g., Sensodyne pilot in Brazil drove double‑digit volume uplift); India growth initiatives (low‑price SKUs) are driving substantial volume gains.
MX:HLNN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed